Ki67 - No evidence for its use in node-positive breast cancer

Nature Reviews Clinical Oncology

Volumn 12, Issue 5, 2015, Pages 296-301

  Andre, Fabrice ^a   Arnedos, Monica ^a   Goubar, Aicha ^a   Ghouadni, Amal ^a   Delaloge, Suzette ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; KI 67 ANTIGEN; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ANTIGEN EXPRESSION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DISTANT METASTASIS; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; BREAST NEOPLASMS; EVIDENCE BASED MEDICINE; FEMALE; LYMPH NODE METASTASIS; METABOLISM; PROCEDURES; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; PROGNOSIS;

EID: 84928825165     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.46     Document Type: Review

References (40)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-Analyses of long-Term outcome 100,000 women in 123 randomised trials. Lancet 370, 432-444 (2012).
2. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2012).
3. Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
4. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
5. Pathmanathan, N. & Balleine, R. L. Ki67 and proliferation in breast cancer. J. Clin. Pathol. 66, 512-516 (2013).
6. Cheang, M. C. et al. Ki-67 index, Her2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
7. de Azambuja, E. et al. Ki-67 as prognostic marker in early breast cancer: a meta-Analysis of published studies involving 12,155 patients. Br. J. Cancer 96, 1504-1513 (2007).
8. Sueta, A. et al. Clinical significance of therapeutic Ki-67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumour subtypes? Surgery 155, 923-935 (2014).
9. Ohno, S. et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki-67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 142, 69-80 (2013).
10. Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann. Oncol. 24, 2206-2223 (2013).
11. Senkus, E. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi7-vi23 (2013).
12. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010).
13. Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenauposal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829-1834 (2010).
14. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01272037?term=NCT01272037&rank=1 (2015).
15. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumour gene expression profiling improve outcomes in patients with breast cancer? Genet. Med. 11, 66-73 (2009).
16. Polley, M. Y. et al. An international Ki-67 reproductibility study. J. Natl Cancer Inst. 105, 1897-1906 (2013).
17. Mikami, Y. et al. Interobserver concordance of Ki-67 labelling index in breast cancer: Japan Breast Cancer Research Group Ki-67 ring study. Cancer Sci. 104, 1539-1543 (2013).
18. Gudlaugsson, E. et al. Comparison of the effect of different techniques for measurement of Ki-67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 61, 1134-1144 (2012).
19. Varga, Z. et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-And Gynecopathologists. PLoS ONE 7, e37379 (2012).
20. Dowsett, M. et al. Assessment of ki67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J. Natl Cancer Inst. 103, 1656-1664 (2011).
21. Penault-Llorca, F. et al. Interpathologists discrepancies in Ki-67 assessment in the PACS01 trial: an independent prognosis factor [abstract]. J. Clin. Oncol. 30 (Suppl.), a543 (2012).
22. Laurinavicius, A. et al. A methodology to ensure and improve accuracy of Ki-67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 16, R35 (2014).
23. Viale, G. et al. Prognostic and predictive value of centrally reviewed Ki-67 labelling index in postmenauposal women with endocrine-responsive breast cancer: results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 26, 5569-5575 (2008).
24. Cuzick, J. et al. Prognostic value of a combined oestrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273-4278 (2011).
25. Regan, M. M. et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl Cancer Inst. 98, 1571-1581 (2006).
26. Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012-6020 (2011).
27. Adjuvant! Online. http://www.adjuvantonline.com/index.jsp (2015).
28. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
29. Bartlett, J. M. et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 11, 266-274 (2010).
30. Penault-Llorca, F. et al. Ki-67 expression and docetaxel efficacy in patients with oestrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2809-2815 (2009).
31. Hugh, J. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27, 1168-1176 (2009).
32. Nitz, U. et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki-67 expression. Ann. Oncol. 25, 1551-1557 (2014).
33. Cortazar, P. et al., Pathological complete response and long-Term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172 (2014).
34. von Minckwitz, G. et al. Response-guided neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol. 31, 3623-3630 (2013).
35. Dieci, M. V. et al. Prognostic value of tumour-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicentre study. Ann. Oncol. 25, 611-618 (2014).
36. Ellis, M. J. et al. Outcome prediction for oestrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumour characteristics. J. Natl Cancer Inst. 100, 1380-1388 (2008).
37. Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403 (2013).
38. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02338310?term=NCT02338310&rank=1 (2015).
39. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00310180?term=NCT00310180&rank=1 (2015).
40. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00433589?term=NCT00433589&rank=1 (2013).